ArticleFrontiers in immunology2026

Targeting the E2F6-TOP2A-DKK1 axis: a novel therapeutic strategy for EMT-driven hepatocellular carcinoma progression.

Mindan Xing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.